Wednesday, December 11, 2013 5:47:17 PM
PacBioToCA Is the Newest Addition to Convey’s Expanding Bioinformatics Suite, Helping to Speed Genomic Research
. .The Convey hybrid-core system allows customers worldwide to enjoy increased application performance with lower ownership costs.
The combination of the PacBioToCA algorithm and a Convey HC system allows our customers to dramatically speed up research for projects in areas such as functional genomics, comparative genomics, and beyond. -- Kevin Corcoran, Pacific Biosciences Richardson, TX (PRWEB) December 11, 2013
Convey Computer™ Corporation announced today the newest addition to Convey’s expanding bioinformatics suite, PacBioToCA, an application that facilitates the assembly of genomes sequenced with Pacific Biosciences® long-read technology. Optimized to take advantage of the highly parallel processing architecture of the Convey hybrid-core (HC) server, PacBioToCA delivers six to fifteen times acceleration.
Researchers running PacBioToCA on Convey HC systems for sequencing and assembly are seeing exceptional results. “The speed up is significant; but even more importantly, researchers are now able to test more parameters,” commented Dr. George Vacek, Director of Convey Computer’s Life Sciences business unit. “Achieving results in a matter of days instead of weeks allows them to refine their approach and get better answers.”
The PacBio® RS II DNA Sequencing System, from Pacific Biosciences (NASDAQ: PACB), helps scientists solve genetically complex problems. Their single-molecule sequencing instruments can generate industry-leading sequence read lengths that dramatically improve genome and transcriptome assembly.
Researchers are attracted to the exceptionally long PacBio reads because they can deliver higher quality assemblies. Prior to the development of algorithms optimized for PacBio read data (such as PacBioToCA), single-pass error rates had been perceived to limit their utility in de novo assembly.
Last year, Dr. Sergey Koren, Bioinformatics Scientist at the National Biodefense Analysis and Countermeasures Center, and his colleagues developed an assembly strategy that uses short sequences (either from PacBio circular consensus sequencing or short read technologies) typical of high-throughput sequencers to correct the errors in PacBio reads. This strategy was subsequently extended to use shorter single-molecule reads to correct the longest ones. These techniques deliver high-accuracy long reads, resulting in gold standard genome assemblies.
For larger genomes, the PacBioToCA algorithm can be time-consuming; therefore, Koren collaborated with Convey to optimize the PacBioToCA algorithm for Convey’s highly parallel HC systems. The optimized version of PacBioToCA runs much faster on the Convey HC servers because the alignment algorithm it uses is significantly faster on a Convey HC-2ex server than the best implementation on a standard server.
“It has been shown that long PacBio reads processed with PacBioToCA lead to such high-quality assemblies, researchers are saved the significant subsequent cost of manual finishing,” explained Kevin Corcoran, Senior Vice President of Market Development at Pacific Biosciences. “The combination of the PacBioToCA algorithm and a Convey HC system allows our customers to dramatically speed up research for projects in areas such as functional genomics, comparative genomics, and beyond.”
Convey’s groundbreaking hybrid-core computing architecture tightly integrates advanced computer architecture and compiler technology with commercial, off-the-shelf hardware—namely Intel® Xeon® processors and Xilinx® Field Programmable Gate Arrays (FPGAs). Particular algorithms are optimized and translated into code that’s loaded onto the FPGAs at runtime to accelerate applications that use these algorithms. The systems help customers dramatically increase performance over industry standard servers while reducing energy costs associated with high-performance computing.
“Adding PacBioToCA to the Convey Bioinformatics Suite reflects our ongoing commitment to the bioinformatics and life sciences community,” concluded Vacek. “We enjoy working with innovators to bring solutions to the industry that will help solve the challenges of the rapidly changing area of sequencing. We look forward to continuing to collaborate with Pacific Biosciences and others on optimization of bioinformatics workflows.”
Convey’s expanding bioinformatics suite is made up of a number of personalities including the Convey GraphConstructor™ for de novo short read assembly, Smith-Waterman for local sequence alignment, and Burrows-Wheeler Aligner for fast reference mapping.
About Convey Computer Corporation
Based in Richardson, Texas, Convey Computer breaks power, performance and programmability barriers with the world’s first hybrid-core computer—a system that marries the low cost and simple programming model of a commodity system with the performance of a customized hardware architecture. Using the Convey hybrid-core systems, customers worldwide in industries such as life sciences, research, big data, and the government/military enjoy order of magnitude performance increases while reducing acquisition and operating costs. http://www.conveycomputer.com
http://www.prweb.com/releases/Convey/PacBio/prweb11058735.htm
Recent PACB News
- Ambry Genetics and PacBio Announce Collaboration to Sequence Up to 7,000 Human Genomes Aimed at Providing Answers for Families Battling Rare Diseases • PR Newswire (US) • 05/15/2024 01:45:00 PM
- Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers • Edgar (US Regulatory) • 05/09/2024 08:33:12 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:21:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 08:12:15 PM
- PacBio Announces First Quarter 2024 Financial Results • PR Newswire (US) • 05/09/2024 08:05:00 PM
- PacBio Announces Preliminary First Quarter 2024 Revenue and Updates 2024 Revenue Guidance • PR Newswire (US) • 04/16/2024 12:05:00 PM
- Estonia National Biobank Selects PacBio to Sequence 10,000 Whole Genomes • PR Newswire (US) • 03/27/2024 12:00:00 PM
- PacBio Grants Equity Incentive Award to New Employee • PR Newswire (US) • 03/22/2024 08:30:00 PM
- PacBio Announces PureTarget™ Repeat Expansion Panel, Expanding its Portfolio of End-to-End Clinical Research Solutions • PR Newswire (US) • 03/12/2024 01:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 10:36:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 10:30:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 10:26:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 10:22:45 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2024 11:32:39 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2024 11:22:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 09:55:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 09:36:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 09:25:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 09:19:42 PM
- PacBio to Present at Upcoming Investor Conferences • PR Newswire (US) • 02/26/2024 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 11:25:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 11:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 11:17:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 11:07:18 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/20/2024 09:17:12 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM